Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Income from Continuing Operations (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Income from Continuing Operations for 6 consecutive years, with 12158000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Income from Continuing Operations rose 13.19% year-over-year to 12158000.0, compared with a TTM value of 36330000.0 through Sep 2025, down 11.78%, and an annual FY2024 reading of 26433000.0, up 49.5% over the prior year.
  • Income from Continuing Operations was 12158000.0 for Q3 2025 at Ovid Therapeutics, down from 4684000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 176007307.0 in Q1 2021 and bottomed at 26000048.0 in Q4 2021.
  • Average Income from Continuing Operations over 5 years is 1954071.0, with a median of 11967770.0 recorded in 2022.
  • The sharpest move saw Income from Continuing Operations surged 978.71% in 2021, then crashed 154.97% in 2025.
  • Year by year, Income from Continuing Operations stood at 26000048.0 in 2021, then surged by 55.75% to 11504789.0 in 2022, then crashed by 33.18% to 15322075.0 in 2023, then surged by 39.61% to 9253000.0 in 2024, then crashed by 31.4% to 12158000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for OVID at 12158000.0 in Q3 2025, 4684000.0 in Q2 2025, and 10235000.0 in Q1 2025.